On January 10, 2024 VerImmune, an early-stage biotechnology company specializing in the development of innovative products based on a novel Virus-inspired Particle (ViP) technology platform, reported a new research collaboration agreement with A*STAR’s Bioprocessing Technology Institute (BTI), a research institute in Singapore with integrated capabilities to assist industry in accelerating process innovation in biomanufacturing (Press release, VerImmune, JAN 10, 2024, View Source [SID1234639188]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The collaboration is centered around platform development and aims to develop a preclinical manufacturing platform, which will facilitate the generation of additional novel ViP-based product candidates for programs beyond VerImmune’s flagship Oncology program which is based on a First-in-Class immunotherapy approach known as Anti-tumor Immune Redirection (AIR).
Since its founding in 2020, VerImmune was originally solely based in the United States having offices and research laboratories at the JLABS@Washington DC incubator. In July 2023, VerImmune was awarded the Second Amgen X NSG Biolabs Golden Ticket Award which allowed the company to secure residency at NSG Biolabs to establish its presence within Asia-Pacific with Singapore as its new regional headquarters. The company intends to use these resources to build up a local platform development team.
"We believe that this collaboration focused on CMC has the potential to further advance and validate our ViP technology as a new modality bringing forth a new class of medicines." said Dr Joshua Wang, Founder and CEO of VerImmune Inc. "As the saying goes ‘the Process is the Product. However, globally, there is only a handful of research institutes that focus on early-stage CMC development. This is critical for any asset’s eventual success but unfortunately often not prioritized part of product development. As we build our presence in Singapore, we recognize the potential of having BTI as a strategic research partner due to their deep expertise in bioprocessing and analytical sciences for biotherapeutics."